Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sylvie Petitjean, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT00877435
First received: April 6, 2009
Last updated: January 28, 2015
Last verified: January 2015
  Purpose
The purpose of this study is to determine whether prize-based contingency management (prizeCM) combined with cognitive behavioral therapy (CBT) is more effective in the treatment of of cocaine-dependent patients compared to CBT only. Patients were randomized to prizeCM + CBT (experimental group) or to CBT (control group) an treated over 24 weeks. It is the first trial of this type in Europe.

Condition Intervention
Cocaine-related Disorders
Behavioral: Cognitive behavioral therapy (CBT)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • retention in treatment, cocaine abstinence [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    cocaine abstinence: at least 3 consecutive weeks of cocaine abstinence, the maximum number of weeks of continous abstinence and proportions of cocaine-free urine samples during the entire 24-week and at 6-month follow-up.


Secondary Outcome Measures:
  • patients' satisfaction with the therapy, clinical measures [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    patients' satisfaction with prize-based contingency management and with CBT


Enrollment: 60
Study Start Date: September 2008
Study Completion Date: October 2014
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
Behavioral: Cognitive behavioral therapy (CBT)
Active Comparator: 2
Cognitive behavioral therapy (CBT)
Behavioral: Cognitive behavioral therapy (CBT)

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cocaine dependence, aged 18 or older, other dependences

Exclusion Criteria:

  • severe somatic, brain, or psychiatric disease, attention deficit disorders with medication methylphenidate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00877435

Locations
Switzerland
Universitäre Psychiatrischen Kliniken
Basel, Switzerland, 4025
Fondation Phenix
Geneva, Switzerland, 1221
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Sylvie A Petitjean, Dr. phil. Psychiatric Hospital of the University of Basel
  More Information

Additional Information:
Responsible Party: Sylvie Petitjean, Dr. phil, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00877435     History of Changes
Other Study ID Numbers: SNF-105314-120675 
Study First Received: April 6, 2009
Last Updated: January 28, 2015
Health Authority: Switzerland: Ethikkommission

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on December 02, 2016